This record was last updated April 15, 2024 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single-arm, multicenter Phase II study of patients with advanced HR+/HER2- breast cancer who are untreated or have failed previous first-line endocrine therapy。The primary objective of this study was to explore the efficacy and safety of the PD-L1 inhibitor adebrelimab in combination with the CDK4/6 inhibitor Dalpiciclib and standard endocrine therapy in advanced HR+/ HER2-breast cancer.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-20.